Abcam plc (ABCM)
收市後：
| 前收市價 | 22.59 |
| 開市 | 22.60 |
| 買盤 | 22.55 x 3100 |
| 賣出價 | 22.91 x 3100 |
| 今日波幅 | 22.55 - 22.64 |
| 52 週波幅 | 12.48 - 25.32 |
| 成交量 | |
| 平均成交量 | 4,623,529 |
| 市值 | 5.18B |
| Beta 值 (5 年，每月) | 0.93 |
| 市盈率 (最近 12 個月) | 2,255.00 |
| 每股盈利 (最近 12 個月) | 0.01 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 2020年3月19日 |
| 1 年預測目標價 | 23.94 |
Insider MonkeyHere’s Why Abcam plc (ABCM) Rose in Q2
Harding Loevner, an asset management company, released its “Global Equity Strategy” second-quarter 2023 investor letter. A copy of the same can be downloaded here. In the second quarter, the strategy returned 8.02% net of fees compared to a 6.35% return for the MSCI All Country World Index and 7% for the MSCI World Index. Slowing inflation […]
- Financial Times
Abcam founder to vote against proposed $5.7bn acquisition by US Danaher
The founder of UK life sciences company Abcam plans to vote against a proposed $5.7bn acquisition by US group Danaher, pushing instead to replace the board and take back the reins as chief executive. Jonathan Milner, who has a 6.1 per cent stake in the Cambridge-based company, argues the $24-a-share deal materially undervalues Abcam, which creates custom antibodies, among other products, for scientists to use in research. Shares in Abcam were trading at $23.36 before the deal was announced in late August, having risen about 40 per cent after Milner launched a campaign for changes on the board in late May.
Insider MonkeyHere’s Why Abcam plc (ABCM) Outperformed in Q2
Headwaters Capital Management, an investment management company, released its second-quarter 2023 investor letter. A copy of the same can be downloaded here. The fund’s portfolio performed exceptionally well in the second quarter of 2023 and gained +17.4% (17.2% net) returns compared to a +4.8% return for the Russell Mid Cap Index. The firm remains optimistic about […]
